Reduction of gastric cancer proliferation and invasion by miR-15a mediated suppression of Bmi-1 translation

Oncotarget

Volumn 7, Issue 12, 2016, Pages 14522-14536

  Wu, Changping ^a,b   Zheng, Xiao ^a,b,c   Li, Xiaodong ^a,b,c   Fesler, Andrew ^c   Hu, Wenwei ^a,b   Chen, Lujun ^a,b   Xu, Bin ^a,b   Wang, Qi ^a,b   Tong, Anthony ^d   Burke, Stephanie ^c   Ju, Jingfang ^c   Jiang, Jingting ^a,b  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b Jiangsu Engineering Research Center for Tumor Immunotherapy   (China)

^c STONY BROOK UNIVERSITY   (United States)

^d BioGenex Inc   (United States)

Author keywords

Bmi 1; Gastric cancer; MiR 15a; Survival

Indexed keywords

BMI1 PROTEIN; MICRORNA 15A; BMI1 PROTEIN, HUMAN; MICRORNA; MIRN15 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; ECTOPIC EXPRESSION; FEMALE; GASTRIC CANCER CELL LINE; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CANCER; STOMACH CARCINOGENESIS; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; APOPTOSIS; CANCER STAGING; CELL MOTION; CELL PROLIFERATION; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROTEIN SYNTHESIS; STOMACH TUMOR; TUMOR CELL CULTURE;

APOPTOSIS; BIOMARKERS, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POLYCOMB REPRESSIVE COMPLEX 1; PROGNOSIS; PROTEIN BIOSYNTHESIS; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84971673814     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7392     Document Type: Article

References (56)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer Journal international du cancer. 2015; 136:E359-386.
3. Thrumurthy SG, Chaudry MA, Chau I and Allum W. Does surgery have a role in managing incurable gastric cancer? Nature reviews Clinical oncology. 2015; 12:676-682.
4. Khalighinejad N, Hariri H, Behnamfar O, Yousefi A and Momeni A. Adenoviral gene therapy in gastric cancer: a review. World J Gastroenterol. 2008; 14:180-184.
5. Tajima Y, Yamazaki K, Makino R, Nishino N, Aoki S, Kato M, Morohara K, Kaetsu T and Kusano M. Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: clinicopathologic significance and genetic background. Clin Cancer Res. 2006; 12:6469-6479.
6. Figueiredo C, Costa S, Karameris A and Machado JC. Pathogenesis of Gastric Cancer. Helicobacter. 2015; 20 Suppl 1:30-35.
7. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513:202-209.
8. Wu WK, Lee CW, Cho CH, Fan D, Wu K, Yu J and Sung JJ. MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene. 2010; 29:5761-5771.
9. Link A, Kupcinskas J, Wex T and Malfertheiner P. Macro-role of microRNA in gastric cancer. Dig Dis. 2012; 30:255-267.
10. Zeng Y. Principles of micro-RNA production and maturation. Oncogene. 2006; 25:6156-6162.
11. Lee YS and Dutta A. MicroRNAs in cancer. Annu Rev Pathol. 2009; 4:199-227.
12. Ambros V. The functions of animal microRNAs. Nature. 2004; 431:350-355.
13. Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, Burge CB and Bartel DP. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science. 2005; 310:1817-1821.
14. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
15. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR and Israel MA. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007; 67:2456-2468.
16. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K and Ju J. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 2007; 13:1668-1674.
17. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433:769-773.
18. Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M, Dumitru CD, Shimizu M, Zupo S, Dono M, Alder H, Bullrich F, Negrini M and Croce CM. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S A. 2004; 101:9740-9744.
19. Wang HJ, Ruan HJ, He XJ, Ma YY, Jiang XT, Xia YJ, Ye ZY and Tao HQ. MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer. 2010; 46:2295-2303.
20. Guo X, Guo L, Ji J, Zhang J, Chen X, Cai Q, Li J, Gu Q, Liu B, Zhu Z and Yu Y. miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer. Biochem Biophys Res Commun. 2010; 398:1-6.
21. Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y, Yao H, Liu X, Ke Y, Si J and Zhou T. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 2010; 20:784-793.
22. Du Y, Xu Y, Ding L, Yao H, Yu H, Zhou T and Si J. Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J Gastroenterol. 2009; 44:556-561.
23. Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y, Li Q, Qiao T, Zhao Q, Nie Y and Fan D. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 2010; 6:e1000879.
24. Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, Choi IJ, Munroe DJ and Green JE. miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics. 2011; 4:79.
25. Craig VJ, Cogliatti SB, Rehrauer H, Wundisch T and Muller A. Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis. Cancer Res. 2011; 71:3616-3624.
26. Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, Zhang WG, Nan KJ, Song TS and Huang C. MicroRNA profiling of human gastric cancer. Mol Med Rep. 2009; 2:963-970.
27. Song F, Yang D, Liu B, Guo Y, Zheng H, Li L, Wang T, Yu J, Zhao Y, Niu R, Liang H, Winkler H, Zhang W, Hao X and Chen K. Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin Cancer Res. 2014; 20:878-889.
28. Zhang X, Yan Z, Zhang J, Gong L, Li W, Cui J, Liu Y, Gao Z, Li J, Shen L and Lu Y. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol. 2011; 22:2257-2266.
29. Takei Y, Takigahira M, Mihara K, Tarumi Y and Yanagihara K. The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. Cancer Res. 2011; 71:1442-1453.
30. Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M and Moriyama M. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res. 2010; 70:2339-2349.
31. Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S, Calin GA and Mukherjee P. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009; 69:9090-9095.
32. Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J and Sakuragi N. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer. 2011; 10:99.
33. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RA, Lao K and Clarke MF. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009; 138:592-603.
34. Xiao G, Tang H, Wei W, Li J, Ji L and Ge J. Aberrant Expression of MicroRNA-15a and MicroRNA-16 Synergistically Associates with Tumor Progression and Prognosis in Patients with Colorectal Cancer. Gastroenterol Res Pract. 2014; 2014:364549.
35. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F and Croce CM. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002; 99:15524-15529.
36. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102:13944-13949.
37. Liu S, Tetzlaff MT, Cui R and Xu X. miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. Am J Pathol. 2012; 181:1823-1835.
38. Guo S, Xu X, Tang Y, Zhang C, Li J, Ouyang Y, Ju J, Bie P and Wang H. miR-15a inhibits cell proliferation and epithelial to mesenchymal transition in pancreatic ductal adenocarcinoma by down-regulating Bmi-1 expression. Cancer Lett. 2014; 344:40-46.
39. Yin T, Wei H, Leng Z, Yang Z, Gou S, Wu H, Zhao G, Hu X and Wang C. Bmi-1 promotes the chemoresistance, invasion and tumorigenesis of pancreatic cancer cells. Chemotherapy. 2011; 57:488-496.
40. Jacobs JJ, Kieboom K, Marino S, DePinho RA and van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999; 397:164-168.
41. Wang Y, Guan Y, Wang F, Huang A, Wang S and Zhang YA. Bmi-1 regulates self-renewal, proliferation and senescence of human fetal neural stem cells in vitro. Neurosci Lett. 2010; 476:74-78.
42. Guo BH, Feng Y, Zhang R, Xu LH, Li MZ, Kung HF, Song LB and Zeng MS. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer. 2011; 10:10.
43. Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, Van Lohuizen M, Campisi J, Wazer DE and Band V. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 2002; 62:4736-4745.
44. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H and Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell. 1991; 65:737-752.
45. Simon JA and Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol. 2009; 10:697-708.
46. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A and van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 1999; 13:2678-2690.
47. Zhang F, Sui L and Xin T. Correlations of BMI-1 expression and telomerase activity in ovarian cancer tissues. Exp Oncol. 2008; 30:70-74.
48. Jiang L, Wu J, Yang Y, Liu L, Song L, Li J and Li M. Bmi-1 promotes the aggressiveness of glioma via activating the NF-kappaB/MMP-9 signaling pathway. BMC Cancer. 2012; 12:406.
49. Silva J, Garcia V, Garcia JM, Pena C, Dominguez G, Diaz R, Lorenzo Y, Hurtado A, Sanchez A and Bonilla F. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res. 2007; 9:R55.
50. Xin T, Zhang FB, Sui GJ and Jin XM. Bmi-1 siRNA inhibited ovarian cancer cell line growth and decreased telomerase activity. Br J Biomed Sci. 2012; 69:62-66.
51. Wang Y, Zhe H, Ding Z, Gao P, Zhang N and Li G. Cancer stem cell marker Bmi-1 expression is associated with basal-like phenotype and poor survival in breast cancer. World J Surg. 2012; 36:1189-1194.
52. Sempere LF, Preis M, Yezefski T, Ouyang H, Suriawinata AA, Silahtaroglu A, Conejo-Garcia JR, Kauppinen S, Wells W and Korc M. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clinical cancer research. 2010; 16:4246-4255.
53. Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, Kong QL, Xu LH, Zhang X, Liu WL, Li MZ, Zhang L, Kang TB, Fu LW, Huang WL, Xia YF, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest. 2009; 119:3626-3636.
54. Choi YJ, Choi YL, Cho EY, Shin YK, Sung KW, Hwang YK, Lee SJ, Kong G, Lee JE, Kim JS, Kim JH, Yang JH and Nam SJ. Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients. Breast Cancer Res Treat. 2009; 113:83-93.
55. Kreso A, van Galen P, Pedley NM, Lima-Fernandes E, Frelin C, Davis T, Cao L, Baiazitov R, Du W, Sydorenko N, Moon YC, Gibson L, Wang Y, Leung C, Iscove NN, Arrowsmith CH, et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2014; 20:29-36.
56. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, Morrison SJ and Clarke MF. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003; 423:302-305.